Collegium Pharma (COLL) Tops Q2 EPS by $1.43

Collegium Pharma (NASDAQ: COLL) reported Q2 EPS of $1.79, $1.43 better than the analyst estimate of $0.36. Revenue for the quarter came in at $82.9 million versus the consensus estimate of $84.77 million.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
• ’Not your father’s Sandisk’: Rosenblatt starts coverage at Buy
• UBS Reiterates Buy Rating on Option Care Health (OPCH) Following Check-in Call Ahead of Quiet Period